36
Participants
Start Date
May 31, 2018
Primary Completion Date
September 6, 2018
Study Completion Date
September 6, 2018
Levamlodipine, Amlodipine
In Part 1, this group of subjects were treated with a single dose of 5 mg levamlodipine maleate tablets (Test Product), then crossed over to receive a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
Amlodipine, Levamlodipine
In Part 1, this group of subjects were treated with a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product), and then crossed over to receive a single dose of 5 mg levamlodipine maleate tablets (Test Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
Collaborative Neuroscience Network, LLC, Long Beach
Lead Sponsor
Collaborators (1)
CSPC Ouyi Pharmaceutical Co., Ltd.
INDUSTRY
Conjupro Biotherapeutics, Inc.
INDUSTRY